On November 20, 2023, JP Morgan analyst Jessica Fye made a significant move by resuming coverage on Nektar Therapeutics (NASDAQ: NKTR) with an Underweight rating. This decision follows the recent announcement from the company regarding the discontinuation of its anti-cancer program, which has led to a downgrade in their evaluation. JP Morgan’s assessment of Nektar Therapeutics’ present circumstances and future potential has prompted this reinstatement. It is imperative for investors to take note of this development as it could have a significant impact on the company’s trajectory.
Updated on: 03/12/2023
Debt to equity ratio: Buy
Price to earnings ratio: Sell
Price to book ratio: Strong Buy
DCF: Strong Buy
7:00 PM (UTC)
Date:01 December, 2023
|Analyst / firm||Rating|
Ladenburg Thalmann & Co.
NKTR Stock Performance: Stable on November 20, 2023, but Revenue Growth and Profitability Require Monitoring
On November 20, 2023, NKTR stock had a relatively stable performance. The stock opened at $0.49 and ranged between $0.49 and $0.51 throughout the day. The trading volume for the day was 11,699 shares, significantly lower than the average volume of 4,826,225 shares over the past three months.
NKTR has a market capitalization of $101.1 million and its earnings growth over the past year has been impressive, with a growth rate of 31.15%. The company’s earnings growth forecast for the next five years is 15.28%.
In terms of revenue growth, NKTR experienced a decline of 9.67% in the previous year.
The stock’s price-to-sales ratio is 4.59, indicating that investors are willing to pay a premium for each dollar of sales generated by the company. The price-to-book ratio is 0.27, indicating that the stock is trading at a significant discount to its book value.
NKTR does not have a P/E ratio listed. Its annual profit for the previous year was -$368.2 million, resulting in a net profit margin of -399.98%.
NKTR operates in the health technology sector, specifically in the pharmaceuticals: major industry. The company is headquartered in San Francisco, California.
Overall, NKTR stock’s performance on November 20, 2023, was relatively stable. However, investors should closely monitor the company’s revenue growth and profitability.
Nektar Therapeutics (NKTR) Stock Analysis: Potential 439.96% Increase in Value According to Analysts
On November 20, 2023, Nektar Therapeutics (NKTR) had a median target price forecast of 2.75, according to two analysts surveyed by CNN Money. The high estimate was 5.00, while the low estimate was 0.50. This median estimate represents a significant increase of 439.96% from the last recorded price of 0.51.
The consensus among five polled investment analysts on NKTR stock was to hold it. This rating has remained steady since November, indicating that there has been no change in the overall sentiment towards the stock.
In terms of financial performance, Nektar Therapeutics reported an earnings per share of -$0.21 for the current quarter. The sales for the same quarter were $21.5 million.
Investors should take note that Nektar Therapeutics is scheduled to report its earnings for the current quarter on February 29. This will provide further insights into the company’s financial health and performance.
Overall, the stock performance of Nektar Therapeutics on November 20, 2023, was influenced by the median target price forecast, which indicated a potential significant increase in value. However, it is important for investors to conduct their own research and analysis before making any investment decisions.